Journal Article

Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure

Hockham, Carinna, Cucui, Andrea, Woodward, Mark, Rose, Matthias, Török, Marietta, Barth, Claudia, Cromm, Krister, Blankestijn, Peter J., Covic, Adrian, Davenport, Andrew, Vernooij, Robin W.M., Bots, Michiel L., Hegbrant, Jörgen, Strippoli, Giovanni F.M., Canaud, Bernard

2023

Overview

Several studies have suggested that patients with kidney failure may benefit from high-dose hemodiafiltration as compared with standard hemodialysis. However, given the limitations of the various published studies, additional data are needed. We conducted a pragmatic, multinational, randomized, controlled trial involving patients with kidney failure who had received high-flux hemodialysis for at least 3 months. All the patients were deemed to be candidates for a convection volume of at least 23 liters per session (as required for high-dose hemodiafiltration) and were able to complete patient-reported outcome assessments. The patients were assigned to receive high-dose hemodiafiltration or continuation of conventional high-flux hemodialysis. The primary outcome was death from any cause. Key secondary outcomes were cause-specific death, a composite of fatal or nonfatal cardiovascular events, kidney transplantation, and recurrent all-cause or infection-related hospitalizations. A total of 1360 patients underwent randomization: 683 to receive high-dose hemodiafiltration and 677 to receive high-flux hemodialysis. The median follow-up was 30 months (interquartile range, 27 to 38). The mean convection volume during the trial in the hemodiafiltration group was 25.3 liters per session. Death from any cause occurred in 118 patients (17.3%) in the hemodiafiltration group and in 148 patients (21.9%) in the hemodialysis group (hazard ratio, 0.77; 95% confidence interval, 0.65 to 0.93). In patients with kidney failure resulting in kidney-replacement therapy, the use of high-dose hemodiafiltration resulted in a lower risk of death from any cause than conventional high-flux hemodialysis. (Funded by the European Commission Research and Innovation; CONVINCE Dutch Trial Register number, NTR7138.).

• Publisher: Massachusetts Medical Society
• Subject: Angioplasty / Chronic Kidney Disease / Clinical Medicine / Clinical Medicine General / Clinical outcomes / Confidence intervals / Convection / Cost analysis / Death / Dialysate / Enrollments / Hemodiafiltration - adverse effects / Hemodiafiltration - methods / Hemodialysis / Hospitalization / Humans / Hypothesis testing / Informed consent / Kidney Failure, Chronic - complications / Kidney Failure, Chronic - mortality / Kidney Failure, Chronic - therapy / Kidney Replacement Therapy / Kidney transplantation / Kidney transplants / Mortality / Nephrology / Patients / Recurrent infection / Renal Dialysis - adverse effects / Renal failure / Renal Insufficiency - etiology / Research centers / Treatment Outcome